Shares of Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) fell 6.6% during mid-day trading on Tuesday . The company traded as low as $0.53 and last traded at $0.56. 46,870 shares were traded during trading, a decline of 74% from the average session volume of 182,658 shares. The stock had previously closed at $0.60.
Matinas Biopharma Stock Down 6.6 %
The company has a market capitalization of $2.85 million, a PE ratio of -0.12 and a beta of 1.54. The business has a fifty day moving average of $0.58.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Featured Stories
- Five stocks we like better than Matinas Biopharma
- High Flyers: 3 Natural Gas Stocks for March 2022
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What is a Dividend King?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
